These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21151883)

  • 1. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
    Wasan EK; Gershkovich P; Zhao J; Zhu X; Werbovetz K; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e913. PubMed ID: 21151883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model.
    Sivak O; Gershkovich P; Lin M; Wasan EK; Zhao J; Owen D; Clement JG; Wasan KM
    Lipids Health Dis; 2011 Aug; 10():135. PubMed ID: 21824435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
    Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
    J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis.
    Italia JL; Kumar MN; Carter KC
    J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
    Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.
    Parvez S; Yadagiri G; Gedda MR; Singh A; Singh OP; Verma A; Sundar S; Mudavath SL
    Sci Rep; 2020 Jul; 10(1):12243. PubMed ID: 32699361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crucial CD8(+) T-lymphocyte cytotoxic role in amphotericin B nanospheres efficacy against experimental visceral leishmaniasis.
    Costa Lima SA; Silvestre R; Barros D; Cunha J; Baltazar MT; Dinis-Oliveira RJ; Cordeiro-da-Silva A
    Nanomedicine; 2014 Jul; 10(5):1021-30. PubMed ID: 24412471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.
    Prajapati VK; Awasthi K; Yadav TP; Rai M; Srivastava ON; Sundar S
    J Infect Dis; 2012 Jan; 205(2):333-6. PubMed ID: 22158723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies.
    Mudavath SL; Talat M; Rai M; Srivastava ON; Sundar S
    Drug Des Devel Ther; 2014; 8():1235-47. PubMed ID: 25214767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.
    Chaurasia M; Singh PK; Jaiswal AK; Kumar A; Pawar VK; Dube A; Paliwal SK; Chourasia MK
    Pharm Res; 2016 Nov; 33(11):2617-29. PubMed ID: 27401407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1277-83. PubMed ID: 22989082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and performance evaluation of amphotericin B transfersomes against resistant and sensitive clinical isolates of visceral leishmaniasis.
    Singodia D; Gupta GK; Verma A; Singh V; Shukla P; Misra P; Sundar S; Dube A; Mishra PR
    J Biomed Nanotechnol; 2010 Jun; 6(3):293-302. PubMed ID: 21179947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis.
    Singh PK; Pawar VK; Jaiswal AK; Singh Y; Srikanth CH; Chaurasia M; Bora HK; Raval K; Meher JG; Gayen JR; Dube A; Chourasia MK
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):1220-1231. PubMed ID: 28780414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.
    Asthana S; Jaiswal AK; Gupta PK; Pawar VK; Dube A; Chourasia MK
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1714-22. PubMed ID: 23357762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.